Disc Medicine Prices Upsized $450 Million Stock Offering

Disc Medicine priced an upsized public offering of 6 million common shares at $75 each, expecting to raise $450 million before expenses; underwriters may buy up to 900,000 additional shares. The offering was initially proposed at $350 million and included pre-funded warrants as an alternative for some investors. Disc plans to use the proceeds to advance research and clinical development, support potential commercialization of bitopertin for erythropoietic and X-linked protoporphyria, fund pre-commercialization work on other candidates, and cover general corporate needs. The offering is expected to close October 22, subject to customary conditions.